| 09/12/2025 15:30 |
Presentation Material Financial Results for the Fiscal Year Ended July31,2025 |
| 09/11/2025 17:05 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors |
| 09/11/2025 17:05 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees |
| 09/10/2025 15:30 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees |
| 09/10/2025 15:30 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator |
| 09/10/2025 15:30 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors |
| 09/10/2025 15:30 |
Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2025 [Japanese GAAP] |
| 07/22/2025 08:30 |
StemRIM Announces Progress of the Additional Phase 2 Clinical Trial on Redasemtide (HMGB1 Fragment Peptide) for Dystrophic Epidermolysis Bullosa |
| 06/16/2025 12:10 |
StemRIM Announces Publication of a Paper on Redasemtide (HMGB1 Fragment Peptide) for Liver Cirrhosis |
| 06/11/2025 15:30 |
Non-consolidated Financial Results for the Nine Months Ended April 30, 2025 [Japanese GAAP] |
| 05/20/2025 15:30 |
StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide, Redasemtide |
| 04/09/2025 15:30 |
StemRIM Announces Setting the Record Date and Holding for Extraordinary General Meeting of Shareholders and Reduction of Capital Stock |
| 04/03/2025 15:30 |
StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide |
| 04/02/2025 11:30 |
StemRIM Announces the Interim Analysis Results for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke |
| 03/12/2025 15:30 |
Non-consolidated Financial Results for the Six Months Ended January 31, 2025 [Japanese GAAP] |
| 03/03/2025 08:30 |
StemRIM Announces the Protocol Amendment for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke |
| 01/15/2025 11:30 |
StemRIM Announces the Extension of the Term for the Tripartite Joint Research Agreement Aimed at Elucidating Skin Anti-Aging Mechanisms |
| 12/23/2024 14:30 |
StemRIM Announces the First Administration of Phase 2 Clinical Trial for Redasemtide Targeting Ischemic Cardiomyopathy |
| 12/12/2024 12:30 |
[Delayed]Non-consolidated Financial Results for Three Months Ended October 31, 2024 |
| 12/12/2024 12:30 |
[Delayed]StemRIM Announces Selection for the AMED Project for Fundamental Technology Development of Regenerative Medicine and Gene Therapy |
| 12/11/2024 16:00 |
StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation |
| 12/09/2024 15:30 |
StemRIM Announces Patent Registration (Europe) for the Use of Redasemtide, as a Therapeutic Indication for Cardiomyopathy and Chronic Heart Failure |
| 12/05/2024 15:30 |
StemRIM Announces Patent Registration in Australia for Peptides Related to the HMGB1 Fragment Peptide, Redasemtide |
| 11/13/2024 15:30 |
StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock |
| 11/05/2024 15:30 |
StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide, Redasemtide |
| 10/31/2024 15:00 |
Presentation Material for Business Plan and Growth Potential |
| 09/25/2024 16:00 |
Notice Regarding Appointment of Director Candidates |
| 09/25/2024 16:00 |
StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company's Executive Officers, Employees, and External Collaborators |
